Atossa Therapeutics, Inc. (ATOS) stock declined over -6.03% intraday to trade at $1.09 a share on NASDAQ. The stock opened with a loss of -6.03% at $1.13 and touched an intraday high of $1.16, falling -6.03% against the last close of $1.16. The stock went to a low of $1.08 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201, an inhalation therapy to improve lung function in severely ill and hospitalized COVID-19 patients; AT-301, a proprietary drug candidate for nasal administration in patients diagnosed with COVID-19; and immunotherapy/chimeric antigen receptor therapy programs for the treatment of breast cancer. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock price is $1.09 as of the last check on Thursday, June 30. During the trading session, ATOS stock reached the peak price of $1.16 while $1.08 was the lowest point it dropped to.
The NASDAQ listed ATOS is part of Biotechnology industry that operates in the broader Health Care sector. Atossa Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases.
Dr. Steven C. Quay FCAP, M.D., Ph.D.
Chairman, CEO & Pres
Mr. Kyle Guse CPA, Esq., CPA
CFO, Gen. Counsel & Sec.
Ms. Heather Rees
VP of Fin. & Accounting
Ms. Delly Behen P.H.R.
VP of Admin. & HR
ATOS stock traded closed the last session at $1.09, which is $-0.07 or -6.03% lower than its previous close of $1.16. ATOS's current trading price is 30.52% lower than its 52-week high of $7.15 where as its distance from 52-week low of 0.84% is -84.76%.
Number of ATOS employees currently stands at -. ATOS operates from 107 Spring Street, Seattle, WA 98104, United States.
Official Webiste of $ATOS is: https://www.atossatherapeutics.com
ATOS stock volume for the day was 1,004,307 shares while in the previous session number of ATOS shares traded was 1,003,325 . The average number of ATOS shares traded daily for last 3 months was 1.83 Million.
The percentage change in ATOS stock occurred in the recent session was -6.03% while the dollar amount for the price change in ATOS stock was $-0.07.
In the recent session, the day high for ATOS stock was $1.16 while the low for ATOS stock touched on the day was $1.08.
The market value of ATOS currently stands at 138.02 Million with its latest stock price at $1.09 and 126.62 Million of its shares outstanding.